SAN DIEGO, Dec. 13 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, today announced that an independent data safety monitoring board (DSMB) has recommended the continuation of both Phase III clinical trials of Sangart's lead blood substitute product, Hemospan(R), under current protocols.
This recommendation follows the DSMB's review of the blinded data from the first one-third of the 830 patients to be enrolled in two ongoing Phase III pivotal studies in Europe. The DSMB will conduct another review after two- thirds of the patients have been enrolled.
"We are pleased to have the DSMB's approval and look forward to advancing these important Phase III studies," commented Dr. Robert Winslow, Chairman, President and CEO of Sangart.
Hemospan is a hemoglobin-based oxygen transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.
Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as oxygen transport agents.
Dr. Robert Winslow, a world-renowned authority in the field of oxygen
transport, founded Sangart in 1998. In the two decades prior to founding
Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of
oxygen transport by cell-free hemoglobin solutions, funded by competitive
grants from the National Institutes of Health and the Department of
Defense. The counterintuitive discoveries by Dr. Winslow's group on the
effective action of oxygen transport agents have been patented and
published in numerous scientific articles. From this experience, Sangart's
lead product, Hemospan, was designed using unique polye
|SOURCE Sangart, Inc.|
Copyright©2007 PR Newswire.
All rights reserved